Deciphering the Dynamics of Leukemogenic Transformation from Clonal Hematopoiesis in Congenital Neutropenia
Gene / mechanism
Clonal haematopoiesis with somatic mutations (CSF3R, TP53, RUNX1, SETBP1) in inherited neutropenia
Summary
Severe congenital neutropenia (CN) and Shwachman-Diamond syndrome (SDS) confer a high cumulative risk of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML), with no established marker of high-risk patients. The authors analysed clonal haematopoiesis in 658 samples from 309 patients, using error-corrected panel sequencing with longitudinal sampling, complemented in selected cases by single-cell DNA sequencing. Clonal haematopoiesis appears in early childhood in 37.7% of CN and 60% of SDS patients, and the somatic mutation burden remains essentially unchanged over decades; CSF3R mutations dominate in CN and TP53 mutations in SDS. In CN, RUNX1 and SETBP1 mutations emerge shortly before transformation, whereas in SDS biallelic TP53-mutant clones expand before transformation and a dominant TP53 clone VAF above 0.074 discriminates patients who progress. Peripheral blood reflects the bone marrow genotype for most key drivers, and transformation follows a defined mutational sequence initiated in childhood.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
For geneticists following these children, the practical message is that molecular monitoring on peripheral blood appears able to detect at-risk clones before transformation. The 0.074 VAF threshold for TP53 in SDS is attractive but not prospectively validated, and the abstract reports neither the number of patients who progressed nor the threshold's performance. It awaits confirmation after peer review before serving as a therapeutic decision criterion.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 6/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime